MAP7D1 is a microtubule-associated protein that stabilizes microtubules and regulates cellular processes including motility, neurite outgrowth, and intracellular transport. Mechanistically, MAP7D1 functions as a microtubule-tethered kinesin-1 activator, enhancing motor protein recruitment and processivity along microtubules 1. It also participates in Wnt5a signaling by forming a feedback loop with Disheveled to facilitate microtubule remodeling and cortical microtubule targeting 2. In neurons, DCLK1-mediated phosphorylation of MAP7D1 at serine 315 promotes axon elongation 3. Clinically, MAP7D1 variants are associated with doxorubicin-induced cardiomyopathy (DIC) in cancer patients; disruption of MAP7D1 function exacerbates doxorubicin cardiotoxicity through impaired autophagy and elevated protein aggregation 4. MAP7D1 upregulation also correlates with increased lymph node metastasis risk in breast cancer through TET1-mediated epigenetic regulation 5. Additionally, a novel MAP7D1 mutation (p.R201W) causes mitotic defects and ribosomal protein accumulation in Shwachman-Diamond syndrome 6, and rare MAP7D1 variants contribute to high myopia heritability 7. These findings establish MAP7D1 as a multifunctional regulator with substantial clinical relevance across cardiovascular, oncological, hematological, and ophthalmological diseases.